A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
Alex CazesOscar BetancourtEdgar EsparzaEvangeline S MoseDawn JaquishEric M WongAlexis A WascherHervé TiriacMarco GymnopoulosAndrew M LowyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Together, these results suggest the promise of agents such as TR1801-ADC as a novel approach to the treatment of pancreatic cancer.